Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NSE - Delayed Quote INR

Innova Captab Limited (INNOVACAP.NS)

884.20
-24.85
(-2.73%)
At close: 3:29:56 PM GMT+5:30
Loading Chart for INNOVACAP.NS
  • Previous Close 909.05
  • Open 912.00
  • Bid --
  • Ask --
  • Day's Range 872.50 - 916.90
  • 52 Week Range 421.35 - 1,260.00
  • Volume 73,211
  • Avg. Volume 81,140
  • Market Cap (intraday) 50.598B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 36.16
  • EPS (TTM) 24.45
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 1,102.50

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also involved in the development, manufacture, and distribution of generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial, erectile dysfunction, anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through its network of distributors and pharmacies, as well as online through various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.

innovacaptab.com

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: INNOVACAP.NS

View More

Performance Overview: INNOVACAP.NS

Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

INNOVACAP.NS
20.73%
S&P BSE SENSEX (^BSESN)
3.20%

1-Year Return

INNOVACAP.NS
92.45%
S&P BSE SENSEX (^BSESN)
9.13%

3-Year Return

INNOVACAP.NS
95.58%
S&P BSE SENSEX (^BSESN)
47.06%

5-Year Return

INNOVACAP.NS
95.58%
S&P BSE SENSEX (^BSESN)
154.50%

Compare To: INNOVACAP.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: INNOVACAP.NS

View More

Valuation Measures

As of 5/5/2025
  • Market Cap

    52.02B

  • Enterprise Value

    54.38B

  • Trailing P/E

    37.20

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.87

  • Price/Book (mrq)

    5.81

  • Enterprise Value/Revenue

    4.58

  • Enterprise Value/EBITDA

    28.53

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.69%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    11.92B

  • Net Income Avi to Common (ttm)

    1.27B

  • Diluted EPS (ttm)

    24.45

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    181.35M

  • Total Debt/Equity (mrq)

    29.17%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: INNOVACAP.NS

View More

People Also Watch